Revenue Recognition and Accounts Receivable Revenue Disaggregation (Table) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Net sales	$ 4,178.2	$ 4,400.1
Brands
Disaggregation of Revenue [Line Items]
Net sales	2,554.1	2,724.6
Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	390.8	328.9
Generics
Disaggregation of Revenue [Line Items]
Net sales	1,233.3	1,346.6
Lipitor
Disaggregation of Revenue [Line Items]
Net sales	440.1	464.6
Norvasc
Disaggregation of Revenue [Line Items]
Net sales	207.8	227.7
Lyrica ®
Disaggregation of Revenue [Line Items]
Net sales	171.7	187.8
Viagra ®
Disaggregation of Revenue [Line Items]
Net sales	129.8	139.6
EpiPen® Auto-Injectors
Disaggregation of Revenue [Line Items]
Net sales	88.8	103.7
Celebrex ®
Disaggregation of Revenue [Line Items]
Net sales	85.2	89.0
Effexor ®
Disaggregation of Revenue [Line Items]
Net sales	77.5	76.6
Zoloft ®
Disaggregation of Revenue [Line Items]
Net sales	73.1	76.6
Creon ®
Disaggregation of Revenue [Line Items]
Net sales	74.7	69.9
Xalabrands
Disaggregation of Revenue [Line Items]
Net sales	53.0	57.9
Amitiza ®
Disaggregation of Revenue [Line Items]
Net sales	41.8	45.9
Xanax ®
Disaggregation of Revenue [Line Items]
Net sales	40.0	45.1
Dymista ®
Disaggregation of Revenue [Line Items]
Net sales	44.0	40.3
Yupelri ®
Disaggregation of Revenue [Line Items]
Net sales	43.7	36.9
Developed Markets | Brands
Disaggregation of Revenue [Line Items]
Net sales	1,298.7	1,403.7
Developed Markets | Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	364.1	312.0
Developed Markets | Generics
Disaggregation of Revenue [Line Items]
Net sales	813.3	855.9
Greater China | Brands
Disaggregation of Revenue [Line Items]
Net sales	569.7	590.9
Greater China | Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	0.0	0.0
Greater China | Generics
Disaggregation of Revenue [Line Items]
Net sales	3.4	1.0
JANZ | Brands
Disaggregation of Revenue [Line Items]
Net sales	249.0	284.0
JANZ | Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	10.3	8.9
JANZ | Generics
Disaggregation of Revenue [Line Items]
Net sales	164.5	189.0
Emerging Markets | Brands
Disaggregation of Revenue [Line Items]
Net sales	436.7	446.0
Emerging Markets | Complex GX and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	16.4	8.0
Emerging Markets | Generics
Disaggregation of Revenue [Line Items]
Net sales	252.1	300.7
Operating Segment | Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	2,476.1	2,571.6
Operating Segment | Greater China
Disaggregation of Revenue [Line Items]
Net sales	573.1	591.9
Operating Segment | JANZ
Disaggregation of Revenue [Line Items]
Net sales	423.8	481.9
Operating Segment | Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	$ 705.2	$ 754.7